Ratings TCM Biotech International Corp.

Equities

4169

TW0004169008

End-of-day quote Taipei Exchange Other stock markets 03:30:00 13/05/2024 am IST			5-day change	1st Jan Change
55.2 ^TWD	0.00%		-0.72%	-5.15%

16/04	TCM Biotech International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	TCM Biotech International Corp. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company's enterprise value to sales, at 3.09 times its current sales, is high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
TCM BIOTECH INTERNATIONAL CORP.	-5.15%	10Cr	-
ELI LILLY AND COMPANY	+29.35%	68TCr	C+
NOVO NORDISK A/S	+30.34%	57TCr	B
JOHNSON & JOHNSON	-3.80%	36TCr	C+
MERCK & CO., INC.	+17.68%	33TCr	B-
ABBVIE INC.	+4.54%	28TCr	C+
ASTRAZENECA PLC	+15.96%	24TCr	B+
NOVARTIS AG	+9.28%	21TCr	B-
ROCHE HOLDING AG	-6.91%	20TCr	A+
AMGEN INC.	+7.91%	17TCr	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes